Absci is a drug and target discovery company. Co. develops an integrated drug creation platform by merging deep learning artificial intelligence (AI) and synthetic biology. The integrated drug creation platform enables target identification, and parallel discovery of biologics and with production cell lines by incorporating biodiversity, high-throughput single cell single cell assays, and deep learning AI models. Co. uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and Co. learns from the data it generates. Co.'s designs are AI-informed and its technology platform is scaffold-agnostic. We show 6 historical shares outstanding datapoints in our coverage of ABSI's shares outstanding history.
Understanding the changing numbers of ABSI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABSI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABSI by allowing them to research ABSI shares outstanding history
as well as any other stock in our coverage universe. |